摘要
中共中央、国务院印发的《“健康中国2030”规划纲要》指出，医药产业要加强疾病预防、新药研发；把精准医疗、生物治疗等作为重点发展方向；同时要加强中药创新。抗肿瘤药物在重大疾病防治以及创新药物研发领域始终走在前沿。随着国家新药创制重大专项资金的大量投入，抗肿瘤药物药物研发领域始终作持续升温，并产生了许多具国际领先水平的科研成果。近年来，根据肿瘤生物学特点发展起来的精准医疗、生物调节及基因疗法等使肿瘤的综合治疗进入了一个新的阶段。
Colorectal cancer is a common gastrointestinal cancer which always diagnosed too late. However, nowadays the median survival of patients has been effectively improved by chemotherapy plus targeted therapy. Targeted drugs on the market can be divided into two categories, monoclonal antibodies and small molecule kinase inhibitors （TKI）. Bevacizumab, cetuximab, panitumumab, ramucirumab are monoclonal antibody. TKIs are as followed：regorafenib, ziv-aflibercept. According to the drug mechanism, bevacizum- ab and panitumumab target at epidermal growth factor receptor（EGFR） on tumor cells. While the remaining four drugs target at vascular endothelial growth factor（VEGF） and its receptor（VEGFR）. Clinical trials of Chinese domestic drugs apatinib and famitinib are un- dergoing. Currently, the main issue of colorectal cancer targeted therapy is how to overcome drug resistance and reducetoxicity. The di- rection of future work is finding new targets, new drugs in colorectal cancer, such as PD-1 inhibitors which may bring new vitality to worldwide patients.
作者
王政
邹建军
李哲
沈素
余俊先
WANG Zheng ZOU Jian-jun LI Zhe SHEN Su YU Jun-xian(Department of Pharmacy, Beifing Friendship Hos-pital, Capital Medical University, Beijing 100050, China Department of New Drug Research and Development, Jiangsu Hengrui Medicine Co. ,Ltd, Shanghai 200122, China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2016年第24期2077-2081,共5页
Chinese Pharmaceutical Journal
基金
国家重大新药创制专项(2010ZX09401-301)
关键词
结直肠癌
靶向药物
表皮生长因子受体
血管内皮生长因子
血管内皮生长因子受体
colorectal cancer
targeted drug
epidermal growth factor receptor
vascular endothelial growth factor
vascular endo- thelial growth factor receptor
